REFERENCES
1. Peloso A, Moeckli B, Delaune V, Oldani G, Andres A, Compagnon P. Artificial intelligence: present and future potential for solid organ transplantation. Transpl Int. 2022;35:10640.
2. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169:467-73.
3. Herbst LR, Herrick-Reynolds K, Bowles Zeiser L, et al. The landscape of nondirected living liver donation in the United States. Transplantation. 2022;106:1600-8.
4. Bambha K, Kim NJ, Sturdevant M, et al. Maximizing utility of nondirected living liver donor grafts using machine learning. Front Immunol. 2023;14:1194338.
5. Linares I, Hamar M, Selzner N, Selzner M. Steatosis in liver transplantation: current limitations and future strategies. Transplantation. 2019;103:78-90.
6. Spitzer AL, Lao OB, Dick AA, et al. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl. 2010;16:874-84.
7. Dutkowski P, Schlegel A, Slankamenac K, et al. The use of fatty liver grafts in modern allocation systems: risk assessment by the balance of risk (BAR) score. Ann Surg. 2012;256:861-8; discussion 868.
8. Lim J, Han S, Lee D, et al. Identification of hepatic steatosis in living liver donors by machine learning models. Hepatol Commun. 2022;6:1689-98.
9. Neil DAH, Minervini M, Smith ML, Hubscher SG, Brunt EM, Demetris AJ. Banff consensus recommendations for steatosis assessment in donor livers. Hepatology. 2022;75:1014-25.
10. Ho S, Kuo E, Allende D, et al. Heterogeneity of hepatic steatosis definitions and reporting of donor liver frozen sections among pathologists: a multicenter survey. Liver Transpl. 2022;28:1540-2.
11. Sun L, Marsh JN, Matlock MK, et al. Deep learning quantification of percent steatosis in donor liver biopsy frozen sections. EBioMedicine. 2020;60:103029.
12. Narayan RR, Abadilla N, Yang L, et al. Artificial intelligence for prediction of donor liver allograft steatosis and early post-transplantation graft failure. HPB. 2022;24:764-71.
13. Gambella A, Salvi M, Molinaro L, et al. Improved assessment of donor liver steatosis using Banff consensus recommendations and deep learning algorithms. J Hepatol. 2024;80:495-504.
14. Jiao J, Tang H, Sun N, Zhang X. Artificial intelligence-aided steatosis assessment in donor livers according to the Banff consensus recommendations. Am J Clin Pathol. 2024;162:401-7.
15. Law JH, Kow AW. Prediction and management of small-for-size syndrome in living donor liver transplantation. Clin Mol Hepatol. 2025;31:S301-26.
16. Kow AWC, Liu J, Patel MS, et al.; ILTS-iLDLT-LTSI SFSS Working Group. Post living donor liver transplantation small-for-size syndrome: definitions, timelines, biochemical, and clinical factors for diagnosis: guidelines from the ILTS-iLDLT-LTSI consensus conference. Transplantation. 2023;107:2226-37.
17. Giglio MC, Zanfardino M, Franzese M, et al. Machine learning improves the accuracy of graft weight prediction in living donor liver transplantation. Liver Transpl. 2023;29:172-83.
18. Chan SC, Liu CL, Lo CM, et al. Estimating liver weight of adults by body weight and gender. World J Gastroenterol. 2006;12:2217-22.
19. Yoneyama T, Asonuma K, Okajima H, et al. Coefficient factor for graft weight estimation from preoperative computed tomography volumetry in living donor liver transplantation. Liver Transpl. 2011;17:369-72.
20. Lemke AJ, Brinkmann MJ, Schott T, et al. Living donor right liver lobes: preoperative CT volumetric measurement for calculation of intraoperative weight and volume. Radiology. 2006;240:736-42.
21. Fan R, Wang J, Du J. Association between body mass index and fatty liver risk: a dose-response analysis. Sci Rep. 2018;8:15273.
22. Park R, Lee S, Sung Y, et al. Accuracy and efficiency of right-lobe graft weight estimation using deep-learning-assisted CT volumetry for living-donor liver transplantation. Diagnostics. 2022;12:590.
23. Ahn Y, Yoon JS, Lee SS, et al. Deep learning algorithm for automated segmentation and volume measurement of the liver and spleen using portal venous phase computed tomography images. Korean J Radiol. 2020;21:987-97.
24. Yang X, Park S, Lee S, et al. Estimation of right lobe graft weight for living donor liver transplantation using deep learning-based fully automatic computed tomographic volumetry. Sci Rep. 2023;13:17746.
25. Hatamizadeh A, Nath V, Tang Y, Yang D, Roth H, Xu D. Swin UNETR: swin transformers for semantic segmentation of brain tumors in MRI images 2022. arXiv 2022;arXiv:2201.01266. Available from https://doi.org/10.48550/arXiv.2201.01266 [accessed 17 March 2026].
26. Oh N, Kim JH, Rhu J, et al. Comprehensive deep learning-based assessment of living liver donor CT angiography: from vascular segmentation to volumetric analysis. Int J Surg. 2024;110:6551-7.
27. Kavur AE, Gezer NS, Barış M, et al. Comparison of semi-automatic and deep learning-based automatic methods for liver segmentation in living liver transplant donors. Diagn Interv Radiol. 2020;26:11-21.
28. Altaf A, Mustafa A, Dar A, et al. Artificial intelligence-based model for the recurrence of hepatocellular carcinoma after liver transplantation. Surgery. 2024;176:1500-6.
29. Chiang CL, Chiu KWH, Chan KSK, et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:169-78.
30. Chiang CL, Chiu KW, Lee FA, Kong FS, Chan AC. Combined stereotactic body radiotherapy and immunotherapy versus transarterial chemoembolization in locally advanced hepatocellular carcinoma: a propensity score matching analysis. Front Oncol. 2021;11:798832.
31. Wong TC, Chiang CL, Lee AS, et al. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: a propensity score matched analysis. Surg Oncol. 2019;28:228-35.
32. Wong TC, Lee VH, Law AL, et al. Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant. Hepatology. 2021;74:2580-94.
33. Mehta N, Frenette C, Tabrizian P, et al. Downstaging outcomes for hepatocellular carcinoma: results from the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. Gastroenterology. 2021;161:1502-12.
34. Tabrizian P, Holzner ML, Mehta N, et al. Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma. JAMA Surg. 2022;157:779-88.
35. Ho KKY, Chiang CL, Wong T, et al. Survival impact of conversion therapy for Barcelona Clinic Liver Cancer (BCLC) stage B and C hepatocellular carcinoma - a propensity score matching analysis. Hepatobiliary Surg Nutr. 2025;14:1063-77.
36. Gotthardt D, Weiss KH, Baumgärtner M, et al. Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation. BMC Gastroenterol. 2009;9:72.
37. Vasconcellos M, Zamith LM. Impact of the MELD score on the survival of hepatocellular carcinoma transplantation patients in Brazil: a systematic review. Rev Col Bras Cir. 2020;46:e20192392.
38. VanDerwerken DN, Wood NL, Segev DL, Gentry SE. The precise relationship between model for end-stage liver disease and survival without a liver transplant. Hepatology. 2021;74:950-60.
39. Raji CG, Chandra SSV, Gracious N, Pillai YR, Sasidharan A. Advanced prognostic modeling with deep learning: assessing long-term outcomes in liver transplant recipients from deceased and living donors. J Transl Med. 2025;23:188.
40. Gangadhar A, Hasjim BJ, Zhao X, et al. Personalized survival benefit estimation from living donor liver transplantation with a novel machine learning method for confounding adjustment. J Hepatol. 2025;83:1116-27.
41. Giglio MC, Dolce P, Yilmaz S, et al.; European Liver and Intestine Transplant Association (ELITA). Development of a model to predict the risk of early graft failure after adult-to-adult living donor liver transplantation: an ELTR study. Liver Transpl. 2024;30:835-47.
42. Barriga-Rodríguez P, Falcón-Cubillo M, Mejías-Trueba M, et al. Pharmacokinetics of different tacrolimus formulations in the early post-liver transplant period: a scoping review. Pharmaceutics. 2025:17.
43. Brunet M, van Gelder T, Åsberg A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41:261-307.
44. Song X, Liu F, Gao H, et al. Compare the performance of multiple machine learning models in predicting tacrolimus concentration for infant patients with living donor liver transplantation. Pediatr Transplant. 2023;27:e14379.
45. Rodríguez-Perálvarez M, Colmenero J, González A, et al.; Chronic Immunosuppression. Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation. Am J Transplant. 2022;22:1671-82.
46. Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol. 2013;59:1193-9.
47. Abrahamsson J, Sternby Eilard M, Rizell M, Bennett W, Åberg F. Reduced calcineurin inhibitor exposure with antibody induction and recurrent hepatocellular carcinoma after liver transplantation. Scand J Gastroenterol. 2022;57:325-32.
48. Grigg SE, Sarri GL, Gow PJ, Yeomans ND. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2019;49:1260-73.
49. Mauro E, Sanduzzi-Zamparelli M, Jutras G, et al. Challenges in Liver Transplantation for Hepatocellular Carcinoma: A Review of Current Controversies. Cancers. 2024:16.
50. Ni X, Wang Q, Gu J, Lu L. Clinical and basic research progress on treg-induced immune tolerance in liver transplantation. Front Immunol. 2021;12:535012.
51. Appenzeller-Herzog C, Hartleif S, Vionnet J. Clinical parameters and biomarkers predicting spontaneous operational tolerance after liver transplantation: a scoping review. Am J Transplant. 2021;21:3312-23.
52. Tsilimigras DI, Mehta R, Moris D, et al. Utilizing machine learning for pre- and postoperative assessment of patients undergoing resection for BCLC-0, A and B Hepatocellular carcinoma: implications for resection beyond the BCLC guidelines. Ann Surg Oncol. 2020;27:866-74.
53. Chaudhary K, Poirion OB, Lu L, Garmire LX. Deep learning-based multi-omics integration robustly predicts survival in liver cancer. Clin Cancer Res. 2018;24:1248-59.
